Morgan Stanley raises Ultragenyx Pharma price target to $20
Morgan Stanley increased its Ultragenyx Pharma price target to $20.00 per share from $18.00, according to a Benzinga ratings update.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.